These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9873600)

  • 41. Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo.
    Tofovic SP; Zacharia LC; Carcillo JA; Jackson EK
    Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):787-92. PubMed ID: 11022970
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
    Burnouf C; Pruniaux MP
    Curr Pharm Des; 2002; 8(14):1255-96. PubMed ID: 12052219
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.
    Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695
    [No Abstract]   [Full Text] [Related]  

  • 44. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
    Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
    J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
    He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
    J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and profile of SCH351591, a novel PDE4 inhibitor.
    Billah M; Cooper N; Cuss F; Davenport RJ; Dyke HJ; Egan R; Ganguly A; Gowers L; Hannah DR; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Naylor R; Oxford J; Peake JC; Piwinski JJ; Runcie KA; Sabin V; Sharpe A; Shih NY; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1621-3. PubMed ID: 12039576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Boss H; Hatzelmann A; Van der Laan IJ; Sterk GJ; Timmerman H
    J Med Chem; 2002 Jun; 45(12):2520-5. PubMed ID: 12036360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
    Buckley GM; Cooper N; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Oxford J; Peake JC; Picken CL; Runcie KA; Sabin V; Sharpe A; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1613-5. PubMed ID: 12039574
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthetic studies on selective type 4 phosphodiesterase (PDE 4) inhibitors. 1. Structure-activity relationships and pharmacological evaluation of 1,8-naphthyridin-2(1H)-one derivatives.
    Takayama K; Iwata M; Hisamichi H; Okamoto Y; Aoki M; Niwa A
    Chem Pharm Bull (Tokyo); 2002 Aug; 50(8):1050-9. PubMed ID: 12192136
    [TBL] [Abstract][Full Text] [Related]  

  • 50. KF19514, a phosphodiesterase 4 and 1 inhibitor, inhibits TNF-alpha-induced GM-CSF production by a human bronchial epithelial cell line via inhibition of PDE4.
    Sasaki K; Manabe H
    Inflamm Res; 2004 Jan; 53(1):31-7. PubMed ID: 15021978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
    Buckley G; Cooper N; Dyke HJ; Galleway F; Gowers L; Gregory JC; Hannah DR; Haughan AF; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Picken CL; Runcie KA; Sabin V; Tuladhar BR; Warneck JB
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2137-40. PubMed ID: 10999488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Orally active PDE4 inhibitor with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Eur J Med Chem; 2004 Jul; 39(7):555-71. PubMed ID: 15236836
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.
    Souness JE; Aldous D; Sargent C
    Immunopharmacology; 2000 May; 47(2-3):127-62. PubMed ID: 10878287
    [No Abstract]   [Full Text] [Related]  

  • 55. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
    Corral LG; Haslett PA; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G
    J Immunol; 1999 Jul; 163(1):380-6. PubMed ID: 10384139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
    Blease K; Burke-Gaffney A; Hellewell PG
    Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
    Alexander RP; Warrellow GJ; Eaton MA; Boyd EC; Head JC; Porter JR; Brown JA; Reuberson JT; Hutchinson B; Turner P; Boyce B; Barnes D; Mason B; Cannell A; Taylor RJ; Zomaya A; Millican A; Leonard J; Morphy R; Wales M; Perry M; Allen RA; Gozzard N; Hughes B; Higgs G
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1451-6. PubMed ID: 12031318
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
    Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
    J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The next generation of PDE4 inhibitors.
    Huang Z; Ducharme Y; Macdonald D; Robichaud A
    Curr Opin Chem Biol; 2001 Aug; 5(4):432-8. PubMed ID: 11470607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of PDE4 inhibitors on lipopolysaccharide-induced priming of superoxide anion production from human mononuclear cells.
    Germain N; Corbel M; Belleguic C; Boichot E; Lagente V
    Mediators Inflamm; 2001 Jun; 10(3):117-23. PubMed ID: 11545248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.